Product InformationRegistration Status: Active
INTEGRILIN IV INFUSION 0.75mg/ML is approved to be sold in Singapore with effective from 1999-11-11. It is marketed by MSD PHARMA (SINGAPORE) PTE LTD, with the registration number of SIN11222P.
This product contains Eptifibatide 0.75mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by Patheon Italia in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.
For treatment of myocardial infarction and acute coronary syndrome.
Mechanism of Action
Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.
* 55 mL/kg/h [patients with coronary artery disease]
Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)
Integrelin | Intrifiban | Eptifibatide |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.